C1-inhibitor autoantibodies in SLE.

Area of Science:

• Immunology
• Rheumatology

Background:

• Acquired C1-inhibitor deficiency is characterized by anti-C1-inhibitor (anti-C1-INH) autoantibodies.
• Data on the prevalence and significance of anti-C1-INH in systemic lupus erythematosus (SLE) are limited.

Purpose of the Study:

• To investigate the prevalence and diagnostic value of anti-C1-INH autoantibodies in SLE patients.
• To explore the correlation between anti-C1-INH levels and clinical/laboratory parameters in SLE.

Main Methods:

• A multicentre study involving 202 SLE patients and 134 healthy controls.
• Measurement of anti-C1-INH IgG levels in sera.
• Analysis of clinical data, including organ involvement, SLEDAI score, and disease duration.
• Assessment of other immunological markers like anti-C1q, anti-dsDNA, and complement levels (C3, C4).

Main Results:

• SLE patients exhibited significantly higher anti-C1-INH IgG levels compared to controls (p = 0.034).
• Elevated anti-C1-INH levels (> or =0.4 U/ml) were detected in 17% of SLE patients versus 4% of controls (p = 0.0003).
• Higher anti-C1-INH levels were associated with increased SLEDAI scores (p = 0.048) and longer disease duration (p = 0.0004).

Conclusions:

• Anti-C1-INH autoantibodies are more common in SLE patients than in healthy individuals.
• Elevated anti-C1-INH levels in SLE correlate with disease activity and chronicity.
• Further research may elucidate the specific role of anti-C1-INH in SLE pathogenesis.